enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $22.8571.

ENGN has been the subject of a number of research analyst reports. Wall Street Zen raised enGene from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of enGene in a research report on Monday, March 9th. Citigroup reiterated a “market outperform” rating on shares of enGene in a research note on Monday, January 5th. Weiss Ratings restated a “sell (d-)” rating on shares of enGene in a research report on Friday, January 9th. Finally, Guggenheim reaffirmed a “buy” rating on shares of enGene in a report on Tuesday, March 10th.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of ENGN. Perceptive Advisors LLC boosted its position in shares of enGene by 179.8% during the 4th quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock worth $52,998,000 after purchasing an additional 3,771,840 shares in the last quarter. Siren L.L.C. acquired a new stake in shares of enGene in the fourth quarter valued at about $30,126,000. Braidwell LP acquired a new stake in shares of enGene in the third quarter valued at about $15,479,000. Janus Henderson Group PLC acquired a new stake in shares of enGene in the fourth quarter valued at about $17,110,000. Finally, Cormorant Asset Management LP boosted its holdings in enGene by 72.1% during the fourth quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock worth $36,120,000 after buying an additional 1,676,405 shares in the last quarter. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Stock Up 2.5%

ENGN stock opened at $7.07 on Thursday. The company has a current ratio of 11.75, a quick ratio of 11.75 and a debt-to-equity ratio of 0.09. enGene has a twelve month low of $2.65 and a twelve month high of $12.25. The company’s 50 day moving average is $9.17 and its two-hundred day moving average is $8.28. The stock has a market cap of $473.62 million, a P/E ratio of -3.14 and a beta of -0.29.

enGene (NASDAQ:ENGN) last issued its earnings results on Monday, March 9th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.11. Research analysts expect that enGene will post -1.56 earnings per share for the current fiscal year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.